14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 23.008 Session: Antibiotic Resistance Gram-Negative Date: Wednesday, March 10, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Incidence of Carbapanemase Resistance Gene (KPC) among Klebsiella pneumoniae isolates and its Clinical Implications B. Yegneswaran, W. Numsuwan, D. Alcid Drexel University College of Medicine / St Peter's University Hospital, New Brunswick, NJ, USA Background: Carbapenem antibiotics (Imipenem, Ertapenem, and Meropenem) idicated for infections caused by extended-spectrum {beta}-lactamase (ESBL) carrying pathogens. Carbapenem resistance has been unusual in isolates of Klebsiella pneumoniae. The aim of this study is to identify the prevalence of KPC positive Klebsiella pneumoniae, and it's clinical significance. Methods: All isolates of Klebsiella pneumoniae species from October 1, 2007 to September 30, 2009 were tested for the presence of KPC gene using the modified Hodge test. Medical records of patients with KPC were studied. Results: Over the period of two-years 40,309 samples were submitted for culture and sensitivity, out of which 7,836 were positive. Of the positives, there were 106 isolates of K pneumoniae and 11 were ESBL positive. Of the ESBL producing isolates, 8 carried the Carbapenem-hydrolyzing -lactamase. Of the eight, three isolates were reported as being susceptible to Imipenem. Although all the eight isolates were resistant using the Hodge test. Piperacillin/Tazobactam (PT) and Vancomycin were the antibiotic used 7 of the 8 patients prior to isolation of Klebsiella pneumoniae resistant to Carbapenems. One patient was excluded in outcome as one patient’s sample was clinically thought to be a contaminant was not treated. 3 patients in whom resistance to carbapenem was reported had their antibiotic was changed to Tigecycline and Polymyxin B resulting in clinical improvement. Of the remaining 4 patients who were reported as sensitive to carbapenem three patients had to undergo a repeat surgery due to clinical deterioration and one patient clinically died. Conclusion: The incidence of KPC gene at our hospital was 7.5%. KPC positive isolatesare rapidly emerging pathogens. It is very important to keep this organism in mind as if not treated there is a 100% probability of having a poor outcome. There is a complete cross resistance to all Carbapenems containing KPC, therefore if KPC is present, the K pneumoniae will be resistant to all Carbapenem regardless of the routine susceptibility testing as shown in three isolates that are KPC positive but susceptible to Imipenem. Current automated systems used for susceptibility testing may not accurately identify all these isolates. We must also control the use of antibiotics specially PT to prevent emergence of KPC positive organisms.
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 23.009 Session: Antibiotic Resistance Gram-Negative Date: Wednesday, March 10, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation In vitro activity of Tigecycline against molecularly defined Carbapenemase producing Acinetobacter baumannii M. Hackel 1 , P. Higgins 2 , H. Seifert 2 , S. Bouchillon 1 , B. Johnson 1 , R. Badal 1 , J. johnson 1 , D. Hoban 1 , S. Hawser 3 , M. Dowzicky 4 1 International Health Management Associates, Inc., Schaumburg, IL, USA, 2 Institute for Medical Microbiology, Cologne, Germany, 3 IHMA Europe Sàrl, Epalinges, Switzerland, 4 Pfizer Inc, Collegeville, PA, USA Background: Acinetobacter baumannii are important opportunistic pathogens with increasing rates of multi-antibiotic resistance due to both intrinsic and acquired mechanisms. Carbapenems are often used to treat these infections, however carbapenem resistance is increasingly reported, leaving few therapeutic options. This resistance is most often associated with acquired or intrinsic OXA-group carbapenemase production. While A. baumannii carry the intrinsic OXA-51- like carbapenemase gene, carbapenem resistance has only been associated with these genes when the insertion sequence ISAba1 is upstream. In this study, we evaluated the in vitro activity of tigecycline against genetically defined A. baumannii from the Tigecycline Evaluation Surveillance Trial. Methods: A total 352 imipenem resistant Acinetobacter baumanii from 35 countries (2004 to 2006) were evaluated. MICs were determined by broth microdilution and interpreted according to CLSI guidelines. Carbapenemase genes were detected by multiplex PCR. Results: All isolates tested in this study contained an OXA-51-like gene. Additional genotypes are listed below. Conclusion: Tigecycline demonstrated excellent in vitro activity against carbapenem resistant A. baumannii regardless of carbapenemase type. Tigecycline’s in vitro activity against isolates with either intrinsic ISAba1-OXA-51 or the acquired oxacillinases (OXA-23, OXA-40 and OXA-58) suggests that it may be effective against resistant isolates of this clinically important pathogen.
Page 1 and 2: When citing these abstracts please
Page 7: When citing these abstracts please
Page 59 and 60:
When citing these abstracts please
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?